Burlulipase

Drug Profile

Burlulipase

Alternative Names: Bacterial lipase; BaLi; Burkholderia bacterial lipase; LU-70274; NM-BL; Project BaLi

Latest Information Update: 22 Feb 2016

Price : $50

At a glance

  • Originator Nordmark Arzneimittel
  • Class Carboxylic ester hydrolases
  • Mechanism of Action Enzyme replacements; Triglyceride modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Exocrine pancreatic insufficiency
  • New Molecular Entity No

Highest Development Phases

  • Phase II Exocrine pancreatic insufficiency

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 22 Feb 2016 Phase-II development is ongoing in Germany and USA
  • 22 May 2013 Phase-I/II clinical trials in Exocrine pancreatic insufficiency in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top